Logo

CombiMatrix Microarray Testing for Stillbirth Analysis

Jan 28, 2016

CombiMatrix has announced the commercial launch of its SNP microarray genetic diagnostic testing of intrauterine fetal demise (IUFD), commonly known as stillbirth genetic testing. The American College of Obstetrician and Gynecologists stated that microarray analysis has proven to show better diagnostic power than karyotyping. The test utilizes SNP microarray technology to detect maternal cell contamination, the company stated.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.